Atlas Trials

Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia

Clinical trial NCT00299702 · COMPLETED

Trial details

NCT number
NCT00299702
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
SchizophreniaPsychotic Disorders
Start date
2006-02-01
Primary completion
2009-01-01
Enrollment
355

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.